Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 6/20 | 0.50 |
| ▸ | RECQL | P46063 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952407 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL13154703 | 0.76 | ALDH1A1 (0.53) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL13237281 | 0.76 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL2923717 | 0.75 | POLB (0.56) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL2923115 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAANPC1MAPT | |
| SCHEMBL2922258 | 0.72 | POLB (0.53) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL2950722 | 0.70 | ALDH1A1 (0.90) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL2924151 | 0.70 | CDKN1A (0.43) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL2918071 | 0.70 | ALDH1A1 (0.51) | ALDH1A1KDM4EGAANPC1MAPT | |
| SCHEMBL13154701 | 0.69 | ALDH1A1 (0.97) | ALDH1A1KDM4EGAANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635840-B1 | THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | claimed |
| US-20080103131-A1 | Therapeutically Active Thiophenepyrimidinone Compounds and Their Use | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-05-01 | — | — | US | claimed |
| US-20050032778-A1 | Therapeutically active thiophenepyrimidinone compounds and their use | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-10 | — | — | US | claimed |
| US-20100249106-A1 | Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-09-30 | — | — | US | disclosed |
| US-7754709-B2 | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds | SOLVAY PHARMACEUTICALS BV (NL) | 2010-07-13 | — | — | US | disclosed |
| US-20080103131-A1 | Therapeutically Active Thiophenepyrimidinone Compounds and Their Use | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-05-01 | — | — | US | disclosed |
| EP-1635840-A1 | THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Solvay Pharmaceuticals B.V. (NL) | 2006-03-22 | — | — | EP | disclosed |
| US-20050032778-A1 | Therapeutically active thiophenepyrimidinone compounds and their use | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| WO-2004110459-A1 | THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032778-A1 | Therapeutically active thiophenepyrimidinone compounds and their use | HSD17B1, HSD17B3, HSD17B2 | ALDH1A1 133/4885KDM4E 2887/4885GAA 722/4885 |
| US-20100249106-A1 | Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds | HSD17B3, HSD17B1, HSD17B2 | ALDH1A1 139/4885KDM4E 2267/4885GAA 1038/4885 |
| US-20080103131-A1 | Therapeutically Active Thiophenepyrimidinone Compounds and Their Use | HSD17B1, HSD17B3, HSD17B2 | ALDH1A1 133/4885KDM4E 2887/4885GAA 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.